{"id":"W2570401170","doi":"10.1007/s40257-016-0246-9","title":"Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)","year":2017,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Etanercept; Plaque psoriasis; Randomized controlled trial; Psoriasis; Pharmacotherapy; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01480968,0.001471645,0.004206884,0.0005186645,0.000442494,0.001334926,0.0007397488,0.001324546,0.001995018],"category_scores_gemma":[0.008212645,0.0006185377,0.007354096,0.0006046483,0.001023384,0.0009797012,0.0005988051,0.00231071,0.0003327114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006457865,"about_ca_system_score_gemma":0.0009741492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003027915,"about_ca_topic_score_gemma":0.0007118681,"domain_scores_codex":[0.990889,0.006286746,0.001036628,0.0007486704,0.0006135064,0.0004255365],"domain_scores_gemma":[0.9916455,0.004147082,0.001876841,0.001089538,0.0005376707,0.0007033385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9664642,0.002139191,0.007377862,0.0005692855,0.00986996,0.00003779331,0.00007005206,0.0003359898,0.003364201,0.00003612201,0.0002506377,0.009484735],"study_design_scores_gemma":[0.6872787,0.2115273,0.07156677,0.000113312,0.02262135,0.0002282199,0.0001189991,0.001074827,0.003425754,0.0003035088,0.00167827,0.00006299717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895931,0.005118478,0.0009764842,0.0001768478,0.0001435745,0.002397354,0.0008070666,0.00004959646,0.0007374056],"genre_scores_gemma":[0.9939191,0.001124311,0.0008417525,0.0003537456,0.0001466767,0.002013479,0.001020623,0.00002455247,0.0005556549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01480968,"threshold_uncertainty_score":0.07832205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06534057836563588,"score_gpt":0.4286594761625303,"score_spread":0.3633188977968944,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}